iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

USFDA Nod for Stroke Drug Lifts Lupin Shares: Indian Pharma Giant Celebrates

24 Jan 2024 , 11:18 AM

On January 24, early trading saw a surge in Lupin shares following the USFDA's clearance of the company's tablets to lower the risk of stroke.

Lupin was trading at Rs 1,455.55 on the BSE at 11:13 a.m., up Rs 16.25, or 1.15% .

'The company has received the tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg, to market a generic equivalent of Xarelto Tablets, 2.5 mg, 10 mg, 15 mg, and 20 mg, of Janssen Pharmaceuticals, Inc,' the business stated.

This product will be produced in Lupin's Indian plant in Pithampur.

Rivaroxaban tablets are prescribed for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and nonvalvular atrial fibrillation. They also help lower the risk of stroke and systemic embolism. It also lowers the chance of significant cardiovascular events in those suffering from coronary artery disease (CAD).

The USFDA approved the company's 40 mg and 80 mg Febuxostat tablets on January 18.

The company's high-margin, low-competition medicine Spiriva is likely to contribute significantly to its Q3 earnings, which are predicted to be among the best. US revenues will remain consistent due to other significant launches like the seizure medication Diazepem gel, the lung problem medication Vilfuro-G, and a stable share in the antiviral drug Darunavir, as well as Suprep, a colonoscopy solution, and albuterol inhalers.

The share had a 52-week high of Rs 1,454.95 on January 23, 2024, and a 52-week low of Rs 628.10 on March 31, 2023.

For feedback and suggestions, write to us at editorial@iifl.com

Lupin Limited - Wikipedia

Related Tags

  • Lupin
  • Stroke
sidebar mobile


Read More

Most Read News

Indian markets end the day on high
23 May 2024|03:59 PM
Markets surge

Markets surge

23 May 2024|03:45 PM
MG Motor India to supply 3000 EVs to Vertelo
23 May 2024|03:46 PM
Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.